Bicycle Therapeutics plc Director Purchases 13,559,062.72 in Stock
BCYC Stock | USD 14.68 0.32 2.13% |
About 70% of Bicycle Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Bicycle Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Bicycle Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Bicycle Therapeutics stock news signals to limit their universe of possible portfolio assets.
Bicycle |
Bicycle Therapeutics plc Director Bros. Advisors Lp Baker bought 985,397 shares of the firms stock in a transaction on Friday, December 13th. The stock was purchased at an average price of 13.76 per share, with a total value of 13,559,062.72. Following the transaction, the director now owns 9,537,643 shares in
Read at thelincolnianonline.com
Bicycle Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bicycle Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bicycle Therapeutics Fundamental Analysis
We analyze Bicycle Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicycle Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicycle Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Bicycle Therapeutics is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Bicycle Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bicycle Therapeutics stock to make a market-neutral strategy. Peer analysis of Bicycle Therapeutics could also be used in its relative valuation, which is a method of valuing Bicycle Therapeutics by comparing valuation metrics with similar companies.
Peers
Bicycle Therapeutics Related Equities
TNYA | Tenaya Therapeutics | 18.44 | ||||
ORIC | Oric Pharmaceuticals | 6.76 | ||||
GLUE | Monte Rosa | 6.45 | ||||
CGEM | Cullinan Oncology | 5.94 | ||||
MGTX | MeiraGTx Holdings | 5.31 | ||||
INBX | Inhibrx | 5.19 | ||||
MLYS | Mineralys Therapeutics, | 4.31 | ||||
STOK | Stoke Therapeutics | 3.36 | ||||
CCCC | C4 Therapeutics | 2.60 | ||||
KROS | Keros Therapeutics | 0.65 | ||||
ACRV | Acrivon Therapeutics, | 0.30 | ||||
SEER | Seer | 0.43 | ||||
MRUS | Merus BV | 0.57 | ||||
ADAG | Adagene | 1.47 | ||||
IGMS | IGM Biosciences | 2.13 | ||||
ANAB | AnaptysBio | 3.00 | ||||
IDYA | Ideaya Biosciences | 3.13 | ||||
ANEB | Anebulo Pharmaceuticals | 10.81 | ||||
IMTXW | Immatics Biotechnologies | 20.83 |
Complementary Tools for Bicycle Stock analysis
When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |